Navigation Links
Royalty Pharma Announces Offer May Lapse (Be Withdrawn)
Date:6/13/2013

are intended to identify forward looking statements but are not the exclusive means of identifying such statements. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur.

Examples of such forward looking statements include (but are not limited to) statements about expected benefits and risks associated with the Further Increased Offer; projections or expectations of profit attributable to shareholders; anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or ratios; statements of plans, objectives or goals of Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements about the future trends in interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements concerning any future Irish, US or other economic environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological or regulatory developments; and statements of assumptions underlying such statements.

Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not under any obligation to update publicly or revise forward looking statements, whether as a result of new information, future events or otherwise.

Rule 8 - Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Irish Takeover Rules, if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Elan, all "dealings" in any
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. PDL BioPharma Provides Second Quarter 2013 Royalty Revenue Guidance of $143 Million
2. Royalty Pharma Files Judicial Review Proceedings
3. Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan
4. Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit
5. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
6. Royalty Pharma Acceptances Announcement
7. Royalty Pharma Responds To Elans Tysabri Valuation
8. Royalty Pharma Response To Elans "Categorical View On Value"
9. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
10. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
11. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented ... that a therapy being developed by Hera Therapeutics Inc. combats ... 70 percent of all cervical cancer. When tested ... of HPV-16, HPV-18 and HPV-11 cells, according to Louise ... who presented the findings at the Seattle ...
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, is ... third international medical cannabis conference taking place at ... France , on October 22, 2014.  The ... stakeholders, such as researchers, health professionals, and patients, ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... 2011 Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... unit, SAFC® ( www.safcglobal.com ), is introducing a novel ... (CHO) cell line. Designed for use in the production ... the first commercially available glutamine synthetase (GS) knockout CHO ...
... YORK, Oct. 27, 2011 Reportlinker.com ... report is available in its catalogue: ... Reimbursement Outlook: Optimizing price and market ... http://www.reportlinker.com/p0165652/Pharma-Pricing-and-Reimbursement-Outlook-Optimizing-price-and-market-access-in-a-recessionary-climate.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Health_Insurance ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 2Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 3Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 4Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 5
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Natural ... Kevin Richardson to restore his own vision from legally blind ... Michaels, prompting an investigative review. , “There is a ... or contacts for everyday function, and most people just think ... to corrective eye surgery that can be pretty risky at ...
(Date:8/22/2014)... factor receptor (EGFR) mutations found in the circulating free ... cell lung cancer (NSCLC) patients correlates well with the ... tyrosine kinase inhibitor (TKI) therapy is approved for EGFR ... standard for determining mutation status is with DNA derived ... not available. A more abundant and less invasive source ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Testosterone ... filed in U.S. courts on behalf of men ... their use of prescription low testosterone therapies, Bernstein ... new claim was filed against Pfizer Inc. on ... suffered life-threatening heart issues due to his use ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- An intensive effort to ... an animal shelter in Florida and euthanized, a new study ... cats to slow their intake into animal control," Dr. Julie ... Florida College of Veterinary Medicine, said in a university news ... wasn,t making a big impact," she explained, "so we wanted ...
(Date:8/22/2014)... artery stenting to open blockages in the kidney ... excluded from modern clinical trials, according to new ... Catheterization and Cardiovascular Interventions today by the ... University Hospitals Case Medical Center,s Sahil Parikh, MD, ... Medicine, Case Western Reserve University School of Medicine ...
Breaking Medicine News(10 mins):Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Neutering Project Curbed Feral Cat Population 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3
... iodinated contrast media during imaging procedures is associated ... of developing hyperthyroidism, according to a report in ... Internal Medicine , one of the JAMA/Archives journals. ... pharmaceutical agents," the authors write as background information. ...
... Reporter , MONDAY, Jan. 23 (HealthDay News) -- Although many ... seriously hurt, the opposite may be true with traumatic brain ... traumatic brain injury in children as young as 2 years, ... even behavior for some time. However, the researchers also found ...
... who routinely accompany older adults to physician office visits ... according to a new study led by researchers at ... authors found that three-quarters of older adults who attend ... over time, nearly always by the same companion. The ...
... release is available in French . Montreal ... three times more likely to develop respiratory or gastrointestinal infections in ... as a Centre d,Hbergement de Soins de Longue Dure (CHLSD). These ... Canadian Medical Association Journal today. "There certainly seems ...
... can help fight both breast cancers and leukemias, according to ... Journal of Experimental Medicine ( http://www.jem.org ). The ... protect other proteins in the cell. , A team led ... found that blocking HSP90 activity rendered normally protected proteins vulnerable ...
... garnered accolades for rescuing skinned knees on the playground ... they,re gaining merit for their offspring,s physical health in ... the journal Psychological Science , Brandeis psychologist Margie ... of British Columbia and the University of California, Los ...
Cached Medicine News:Health News:Use of iodinated contrast media in imaging procedures appears to affect thyroid function 2Health News:Severe Brain Injury When Young May Have Long-Term Effects 2Health News:Severe Brain Injury When Young May Have Long-Term Effects 3Health News:Severe Brain Injury When Young May Have Long-Term Effects 4Health News:Going to physician visits with older loved ones could improve care 2Health News:Emergency room visits risky for elderly residents from long-term care facilities 2Health News:Nurturing mothers rear physically healthier adults 2Health News:Nurturing mothers rear physically healthier adults 3
... The 1081 is an all-in-one drape ... The drape includes a pouch with filter ... finger cot. 64 inches (164cm) TUR ... Elastic aperture, Neoprene finger cot, Fluid collection ...
... Both the Penilab IV and the Penilab V ... studies. Model 1060 is similar to the Model ... nor can one be added later. The Penilab ... including all of the accessories you'll need to get ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... II SP MRI-Compatible Anesthesia System is perfect for ... than one type of anesthetic agent. , ... due to its wider stance, has a larger ... bellows assembly is utilized in both the Integra ...
Medicine Products: